These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 14528049

  • 1. Huntington's disease.
    MacDonald ME, Gines S, Gusella JF, Wheeler VC.
    Neuromolecular Med; 2003; 4(1-2):7-20. PubMed ID: 14528049
    [Abstract] [Full Text] [Related]

  • 2. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH, Cheng PH, Banta H, Piotrowska-Nitsche K, Yang JJ, Cheng EC, Snyder B, Larkin K, Liu J, Orkin J, Fang ZH, Smith Y, Bachevalier J, Zola SM, Li SH, Li XJ, Chan AW.
    Nature; 2008 Jun 12; 453(7197):921-4. PubMed ID: 18488016
    [Abstract] [Full Text] [Related]

  • 3. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH, Charles V, Williams M, Miller G, Whetsell WO, Tagle DA.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):1035-45. PubMed ID: 10434303
    [Abstract] [Full Text] [Related]

  • 4. [From gene to disease; HD gene and Huntington disease].
    Maat-Kievit JA, Losekoot M, Roos RA.
    Ned Tijdschr Geneeskd; 2001 Nov 03; 145(44):2120-3. PubMed ID: 11723754
    [Abstract] [Full Text] [Related]

  • 5. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
    Kenney C, Powell S, Jankovic J.
    Mov Disord; 2007 Jan 03; 22(1):127-30. PubMed ID: 17115386
    [Abstract] [Full Text] [Related]

  • 6. Genetics and neuropathology of Huntington's disease.
    Reiner A, Dragatsis I, Dietrich P.
    Int Rev Neurobiol; 2011 Jan 03; 98():325-72. PubMed ID: 21907094
    [Abstract] [Full Text] [Related]

  • 7. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
    Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME, Gusella JF.
    Somat Cell Mol Genet; 1998 Jul 03; 24(4):217-33. PubMed ID: 10410676
    [Abstract] [Full Text] [Related]

  • 8. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?
    Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O.
    Mech Ageing Dev; 2006 Feb 03; 127(2):208-12. PubMed ID: 16274727
    [Abstract] [Full Text] [Related]

  • 9. The use of transgenic and knock-in mice to study Huntington's disease.
    Hickey MA, Chesselet MF.
    Cytogenet Genome Res; 2003 Feb 03; 100(1-4):276-86. PubMed ID: 14526189
    [Abstract] [Full Text] [Related]

  • 10. HD CAG-correlated gene expression changes support a simple dominant gain of function.
    Jacobsen JC, Gregory GC, Woda JM, Thompson MN, Coser KR, Murthy V, Kohane IS, Gusella JF, Seong IS, MacDonald ME, Shioda T, Lee JM.
    Hum Mol Genet; 2011 Jul 15; 20(14):2846-60. PubMed ID: 21536587
    [Abstract] [Full Text] [Related]

  • 11. Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice.
    Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC.
    Hum Mol Genet; 2006 Jun 15; 15(12):2015-24. PubMed ID: 16687439
    [Abstract] [Full Text] [Related]

  • 12. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH, Qin ZH.
    Acta Pharmacol Sin; 2006 Oct 15; 27(10):1287-302. PubMed ID: 17007735
    [Abstract] [Full Text] [Related]

  • 13. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
    Wyttenbach A, Swartz J, Kita H, Thykjaer T, Carmichael J, Bradley J, Brown R, Maxwell M, Schapira A, Orntoft TF, Kato K, Rubinsztein DC.
    Hum Mol Genet; 2001 Aug 15; 10(17):1829-45. PubMed ID: 11532992
    [Abstract] [Full Text] [Related]

  • 14. A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.
    Cummings DM, Alaghband Y, Hickey MA, Joshi PR, Hong SC, Zhu C, Ando TK, André VM, Cepeda C, Watson JB, Levine MS.
    J Neurophysiol; 2012 Jan 15; 107(2):677-91. PubMed ID: 22072510
    [Abstract] [Full Text] [Related]

  • 15. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
    Truant R, Atwal RS, Burtnik A.
    Prog Neurobiol; 2007 Nov 15; 83(4):211-27. PubMed ID: 17240517
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Rising AC, Xu J, Carlson A, Napoli VV, Denovan-Wright EM, Mandel RJ.
    Exp Neurol; 2011 Apr 15; 228(2):173-82. PubMed ID: 21192926
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Experimental models of HD and reflection on therapeutic strategies.
    Kim J, Bordiuk OL, Ferrante RJ.
    Int Rev Neurobiol; 2011 Apr 15; 98():419-81. PubMed ID: 21907096
    [Abstract] [Full Text] [Related]

  • 19. Huntington's disease: translating a CAG repeat into a pathogenic mechanism.
    MacDonald ME, Gusella JF.
    Curr Opin Neurobiol; 1996 Oct 15; 6(5):638-43. PubMed ID: 8937828
    [Abstract] [Full Text] [Related]

  • 20. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.
    Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, Dawson VL, Dawson TM.
    Proc Natl Acad Sci U S A; 1996 May 14; 93(10):5037-42. PubMed ID: 8643525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.